Marcos Jose Garcia de Lima
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Hospital Universitário Clementino Fraga/CCS
Unidade:
Hospital Universitário Clementino Fraga/CCS
Departamento:
Divisão Recursos Humanos/HU
Formação:
-
Texas A&M University System
| Especialização - Residência medica | 1994 - 1996
-
Universidade Federal do Rio de Janeiro
Medicina Interna | Mestrado | 1988 - 1990
-
Universidade Federal do Rio de Janeiro
| Especialização - Residência medica | 1988 - 1990
-
Universidade Federal do Rio de Janeiro
Medicina | Graduação | 1981 - 1986
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(91.34% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis | 10.1200/jco.2015.66.3476 | rint |
| Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients | 10.1038/s41375-020-0812-2 | 2021 |
| History of drug use in allogeneic hematopoietic cell transplant recipients | 10.1038/s41409-020-01058-z | 2021 |
| Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation | 10.1038/s41409-020-01080-1 | 2021 |
| A case of neurocognitive deficit strongly related to dasatinib therapy | 10.1016/j.htct.2019.01.003 | 2020 |
| Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor? | 10.3324/haematol.2018.215202 | 2020 |
| Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research | 10.3324/haematol.2019.220756 | 2020 |
| Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation | 10.1111/nep.13712 | 2020 |
| Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia | 10.3389/fonc.2020.00327 | 2020 |
| Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report | 10.1182/bloodadvances.2019001266. | 2020 |
| Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation | 10.1038/s41409-020-0957-7 | 2020 |
| Influence of gut microbiome on multiple myeloma: friend or foe? | 10.1136/jitc-2020-000576 | 2020 |
| COVID-19 presenting as a viral exanthem and detected during admission prescreening in a hematopoietic cell transplant recipient | 10.1016/j.htct.2020.06.002 | 2020 |
| Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | 10.6004/jnccn.2020.0021 | 2020 |
| Cryopreservation of hematopoietic cells using a pre-constituted, protein-free cryopreservative solution with 5% dimethyl sulfoxide | 10.1016/j.jcyt.2020.05.006 | 2020 |
| Harnessing the Immune System to Overcome Cytokine Storm and Reduce Viral Load in COVID-19: A Review of the Phases of Illness and Therapeutic Agents | 10.2139/ssrn.3603857 | 2020 |
| Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia | 10.1080/10428194.2020.1789630 | 2020 |
| Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients | 10.1080/10428194.2020.1783444 | 2020 |
| Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma | 10.3389/fimmu.2020.01941 | 2020 |
| Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol-min. A historically controlled clinical trial | 10.1002/hon.2789 | 2020 |
| Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis | 10.1016/j.bbmt.2020.08.036 | 2020 |
| Analysis of epigenetic aging and : Factors controlling the speed and direction | 10.1177/1535370220947015 | 2020 |
| Improving patient access to modern myeloma therapy in Latin America: first step, know what your problem really is | 10.1080/10428194.2020.1821013 | 2020 |
| Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administration | 10.1038/s41409-020-0812-x | 2020 |
| Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts | 10.1002/ajh.25338 | 2019 |
| Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma | 10.1016/j.clml.2018.12.022 | 2019 |
| Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation | 10.1016/j.bbmt.2018.11.005 | 2019 |
| Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells | 10.1111/acel.12897 | 2019 |
| Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia | 10.1016/j.clml.2018.11.001 | 2019 |
| Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse | 10.1016/j.bbmt.2018.12.764 | 2019 |
| Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes | 10.1038/s41409-019-0444-1 | 2019 |
| The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia | 10.1182/bloodadvances.2018027003 | 2019 |
| Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study | 10.1038/s41409-019-0521-5 | 2019 |
| Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected | 10.1080/10428194.2019.1573367 | 2019 |
| Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study | 10.1038/s41375-019-0477-x | 2019 |
| A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia | 10.1158/1078-0432.CCR-18-3886 | 2019 |
| Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study | 10.1016/j.bbmt.2019.04.007 | 2019 |
| Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission | 10.1182/bloodadvances.2019000050 | 2019 |
| Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases | 10.1016/j.htct.2019.01.002 | 2019 |
| Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells | 10.1038/s41598-019-51287-6 | 2019 |
| Organ sparing of linac-based targeted marrow irradiation over total body irradiation | 10.1002/acm2.12742 | 2019 |
| Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents | 10.1038/s41409-018-0269-3 | 2019 |
| Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis | 10.1080/17474086.2019.1562331 | 2019 |
| Posttransplant maintenance therapy for acute leukemias | 10.1097/MOH.0000000000000484 | 2019 |
| Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | 10.6004/jnccn.2019.0028 | 2019 |
| Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation | 10.1080/10428194.2017.1390234 | 2018 |
| Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis | 10.1016/j.bbmt.2017.11.003 | 2018 |
| Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study | 10.1016/j.bbmt.2017.11.033 | 2018 |
| Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia | 10.1016/j.bbmt.2017.11.025 | 2018 |
| Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation | 10.1016/j.bbmt.2017.12.784 | 2018 |
| Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma | 10.1080/10428194.2017.1408086 | 2018 |
| Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes | 10.1016/j.clml.2017.10.001 | 2018 |
| Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models | 10.1371/journal.pone.0191358 | 2018 |
| Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion | 10.1182/blood-2017-07-798751 | 2018 |
| Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2018.01.001 | 2018 |
| Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation | 10.1158/1078-0432.CCR-18-0449 | 2018 |
| Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia | 10.1155/2018/9807047 | 2018 |
| CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes | 10.1016/j.bbmt.2018.06.016 | 2018 |
| Aberrant GSK3β nuclear localization promotes AML growth and drug resistance | 10.1182/bloodadvances.2018016006 | 2018 |
| FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials | 2018 | |
| Management of important adverse events associated with inotuzumab ozogamicin: expert panel review | 10.1038/s41409-017-0019-y | 2018 |
| Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients | 10.1038/bmt.2016.322 | 2017 |
| Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia | 10.1002/ajh.24575 | 2017 |
| Isolated skin relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplant | 10.1016/j.bjhh.2016.11.003 | 2017 |
| Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission | 10.1002/cncr.30536 | 2017 |
| Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide | 10.1182/blood-2016-09-737825 | 2017 |
| Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis | 10.1002/cncr.30567 | 2017 |
| Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era | 10.1080/10245332.2017.1279842 | 2017 |
| Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia | 10.1002/cncr.30737 | 2017 |
| Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia | 10.1016/j.bbmt.2017.04.003 | 2017 |
| Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery | 10.1016/j.bbmt.2017.05.002 | 2017 |
| Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies | 10.18632/oncotarget.20094 | 2017 |
| Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study | 10.1111/bjh.14954 | 2017 |
| Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | 10.1200/CCI.17.00055 | 2017 |
| Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology | 10.6004/jnccn.2017.0116 | 2017 |
| Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle | 10.3389/fonc.2017.00287 | 2017 |
| Going home for the holidays? Take a shortcut! | 10.1038/bmt.2016.366 | 2017 |
| Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma | 10.1038/bcj.2017.60 | 2017 |
| Nivolumab before and after allogeneic hematopoietic cell transplantation | 10.1038/bmt.2017.44 | 2017 |
| Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis | 10.1038/leu.2017.42 | 2017 |
| Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes | 10.1111/bjh.13975 | 2016 |
| Repression of GSK3 restores NK cell cytotoxicity in AML patients | 10.1038/ncomms11154 | 2016 |
| Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia | 10.1016/j.bbmt.2016.02.013 | 2016 |
| Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis | 10.1002/cncr.30140 | 2016 |
| A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity | 10.1158/1535-7163.MCT-15-0566 | 2016 |
| Long-Term Outcomes after Treatment with Clofarabine-±-Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome | 10.1016/j.bbmt.2016.06.023 | 2016 |
| Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era | 10.1111/bjh.14228 | 2016 |
| Intra-osseous Co-transplantation of CD34-selected Umbilical Cord Blood and Mesenchymal Stromal Cells | 10.15761/HMO.1000105 | 2016 |
| Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience | 10.1016/j.bjhh.2016.07.003 | 2016 |
| Myeloid-derived suppressor cells: The green light for myeloma immune escape | 10.1016/j.blre.2016.04.002 | 2016 |
| The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia | 10.1186/s40425-016-0188-z | 2016 |
| Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant | 10.1038/bmt.2016.104 | 2016 |
| Resistant or Sensitive: Time is of the Essence | 10.1016/j.bbmt.2016.06.028 | 2016 |
| Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | 10.1016/j.clml.2014.07.001 | 2015 |
| Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study | 10.1016/j.bbmt.2014.11.007 | 2015 |
| Traffic Light: prognosis-based eligibility for clinical trials of hematopoietic SCT in adults with sickle cell anemia | 10.1038/bmt.2015.11 | 2015 |
| Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation | 10.1182/blood-2015-01-607366 | 2015 |
| Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment | 10.1016/j.bbmt.2015.04.022 | 2015 |
| Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation | 10.1016/j.bbmt.2015.03.023 | 2015 |
| Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome | 10.1038/bmt.2015.82 | 2015 |
| Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients | 10.1016/j.bbmt.2015.06.007 | 2015 |
| Better allele-level matching improves transplant-related mortality after double cord blood transplantation | 10.3324/haematol.2015.127787 | 2015 |
| Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better? | 10.3109/10428194.2014.949262 | 2015 |
| Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia | 10.1053/j.seminhematol.2015.03.005 | 2015 |
| Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations | 10.1016/j.bbmt.2015.07.033 | 2015 |
| New approaches to transplantation in acute myelogenous leukemia | 10.1182/asheducation-2015.1.596 | 2015 |
| Aging and transplanting graciously | 10.1016/S2352-3026(15)00193-3 | 2015 |
| The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation | 10.1016/j.clml.2013.08.006 | 2014 |
| Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease | 10.1038/leu.2013.253 | 2014 |
| Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research | 10.1016/j.bbmt.2013.10.018 | 2014 |
| Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen-Identical Sibling Transplantations for Chronic Lymphocytic Leukemia? | 10.1016/j.bbmt.2013.11.032 | 2014 |
| Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy | 10.1002/ajh.23655 | 2014 |
| The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.clml.2014.01.002 | 2014 |
| Music Therapy for Patients Who Have Undergone Hematopoietic Stem Cell Transplant | 10.1155/2014/742941 | 2014 |
| Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival | 10.1016/j.bbmt.2014.03.013 | 2014 |
| Is there an expiration date for a cord blood unit in storage? | 10.1038/bmt.2014.92 | 2014 |
| Low rate of infusional toxicity after expanded cord blood transplantation | 10.1016/j.jcyt.2013.12.011 | 2014 |
| Transmission of lupus anticoagulant by allogeneic stem cell transplantation | 10.1016/j.bjhh.2014.05.008 | 2014 |
| Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation | 10.1016/j.bbmt.2014.06.022 | 2014 |
| Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens | 10.1016/j.bbmt.2014.05.020 | 2014 |
| Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning | 10.1200/JCO.2013.54.0625 | 2014 |
| Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors | 10.1016/j.bbmt.2014.08.013 | 2014 |
| Proceedings from the National Cancer Institute?s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation | 10.1016/j.bbmt.2013.08.012 | 2014 |
| Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2013.11.017 | 2014 |
| Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology | 10.1200/JCO.2013.53.7076 | 2014 |
| Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Are We Closer to Knowing Who Needs It? | 10.1007/s11899-014-0207-4 | 2014 |
| The end of knight-errantry in GVHD studies | 10.1182/blood-2014-09-599175 | 2014 |
| Utility of the p53 mutant protein in patients with low-risk myelodysplastic syndrome | 10.1016/j.bjhh.2014.03.014 | 2014 |
| Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?--See paper by Holanda K et al. on pages 29-34. | 10.5581/1516-8484.20140003 | 2014 |
| Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature | 10.1007/s12308-011-0123-7 | 2013 |
| Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis | 10.1038/bmt.2012.110 | 2013 |
| Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission | 10.1016/j.bbmt.2012.09.002 | 2013 |
| Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation | 10.1111/bjh.12210 | 2013 |
| Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation | 10.1038/leu.2012.319 | 2013 |
| Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia | 10.1038/bmt.2012.195 | 2013 |
| Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study | 10.1016/j.bbmt.2012.12.001 | 2013 |
| Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study | 10.1002/ajh.23371 | 2013 |
| Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin | 10.1016/j.clml.2012.12.003 | 2013 |
| High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma | 10.1016/j.bbmt.2013.03.008 | 2013 |
| Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL | 10.1038/bmt.2012.114 | 2013 |
| Ex Vivo T Cell-Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission | 10.1016/j.bbmt.2013.02.018 | 2013 |
| Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience | 10.1038/bmt.2013.33 | 2013 |
| Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation | 10.1182/blood-2013-02-481945 | 2013 |
| Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.clml.2013.02.023 | 2013 |
| Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization | 10.1002/ajh.23499 | 2013 |
| Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit | 10.1200/JCO.2013.50.5867 | 2013 |
| A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma | 10.1016/j.bbmt.2013.07.008 | 2013 |
| Peripheral blood stem cell yield calculated using preapheresis absolute CD34+ cell count, peripheral blood volume processed, and donor body weight accurately predicts actual yield at multiple centers | 10.1111/trf.12435 | 2013 |
| Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI | 10.1182/blood-2013-07-514448 | 2013 |
| Epigenetic therapy in allogeneic hematopoietic stem cell transplantation | 10.5581/1516-8484.20130034 | 2013 |
| Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes | 10.6004/jnccn.2013.0145 | 2013 |
| Mesenchymal stromal cell expansion for cord-blood engraftment | 2013 | |
| Cord Blood Transplantation: Can We Make it Better? | 10.3389/fonc.2013.00238 | 2013 |
| Preventing Acute Leukemia Relapse after Allogeneic Transplants: How to Move Forward? | 10.1016/j.bbmt.2012.11.009 | 2013 |
| Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR | 10.1038/bmt.2011.61 | 2012 |
| Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant | 10.3109/10428194.2011.634039 | 2012 |
| Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant | 10.3109/10428194.2011.631159 | 2012 |
| Adherence of stem cell transplant recipients receiving glucocorticoid therapy to an exercise-based rehabilitation program | 10.1007/s00520-011-1352-0 | 2012 |
| Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes | 10.1016/j.bbmt.2011.08.011 | 2012 |
| Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome | 10.1200/JCO.2011.38.3265 | 2012 |
| Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2012.07.003 | 2012 |
| Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era | 10.1182/blood-2012-02-409763 | 2012 |
| Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results | 10.1182/blood-2012-03-417808 | 2012 |
| Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2012.06.010 | 2012 |
| Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture | 10.1056/NEJMoa1207285 | 2012 |
| Emerging Therapies in Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2011.10.022 | 2012 |
| Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center | 10.3109/10428194.2011.644547 | 2012 |
| Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study | 10.1200/jco.2010.30.6357 | 2011 |
| Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence | 10.1038/bmt.2010.102 | 2011 |
| Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning | 10.3109/10428194.2010.529205 | 2011 |
| Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS | 10.1016/j.bbmt.2010.09.022 | 2011 |
| Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission | 10.1016/j.bbmt.2010.11.012 | 2011 |
| Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 Loci | 10.1016/j.bbmt.2010.10.017 | 2011 |
| Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell-Depleted Haploidentical Stem Cell Transplantation | 10.1016/j.bbmt.2010.11.020 | 2011 |
| Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations | 10.1182/blood-2010-08-302679 | 2011 |
| Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation | 10.1200/JCO.2010.34.2873 | 2011 |
| Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life | 10.1016/j.bbmt.2011.02.007 | 2011 |
| Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome | 10.1016/j.bbmt.2011.05.018 | 2011 |
| Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation | 10.1111/j.1537-2995.2011.03176.x | 2011 |
| Steroid-Refractory Acute GVHD: Predictors and Outcomes | 10.1155/2011/601953 | 2011 |
| Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib | 10.1016/j.bbmt.2011.07.011 | 2011 |
| Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation | 10.1182/blood-2011-06-362111 | 2011 |
| Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation | 2011 | |
| The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings | 10.1007/s11899-010-0075-5 | 2011 |
| Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome: A Review | 10.1053/j.seminoncol.2011.04.012 | 2011 |
| Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors | 10.1016/j.clml.2011.03.028 | 2011 |
| Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia | 10.1097/MOH.0b013e328343b858 | 2011 |
| Hematopoietic stem cell transplantation for Hodgkin's disease | 10.5581/1516-8484.20110004 | 2011 |
| Mesenchymal stem cells in ex vivo cord blood expansion | 10.1016/j.beha.2010.11.001 | 2011 |
| The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era | 10.5581/1516-8484.20110122 | 2011 |
| Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation | 10.1097/MOH.0b013e32834b6158 | 2011 |
| Advances in haploidentical stem cell transplantation | 10.5581/1516-8484.20110060 | 2011 |
| Humoral HLA sensitization matters in CBT outcome | 10.1182/blood-2011-10-382630 | 2011 |
| HLA matching of CB: it's complicated | 10.1182/blood-2011-08-369066 | 2011 |
| Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes | 10.1038/bmt.2009.253 | 2010 |
| Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT | 10.1038/bmt.2009.189 | 2010 |
| Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I | 10.1002/cncr.25092 | 2010 |
| Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia | 10.1182/blood-2009-10-249128 | 2010 |
| Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation | 10.1016/j.bbmt.2009.12.004 | 2010 |
| Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2009.12.532 | 2010 |
| Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type | 10.3324/haematol.2009.016758 | 2010 |
| Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome | 10.1002/cncr.25500 | 2010 |
| Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure | 10.1200/JCO.2010.28.8852 | 2010 |
| A randomized study comparing chemotherapy followed by G-CS F alone or in combination with GM-CS F for mobilization of peripheral blood stem cells in patients with non-Hodgkin?s lymphomas | 2010 | |
| Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy | 10.3109/10428194.2010.501534 | 2010 |
| Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy | 10.1182/blood-2010-07-296392 | 2010 |
| The Impact of pre-stem cell transplant ferritin level on late transplant complications: an analysis to determine the potential role of iron overload on late transplant outcomes | 2010 | |
| Overcoming the barriers to umbilical cord blood transplantation | 10.3109/14653240903440111 | 2010 |
| Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome | 10.1016/j.bbmt.2009.10.018 | 2010 |
| NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation | 10.1016/j.bbmt.2010.04.004 | 2010 |
| Umbilical cord blood transplantation | 2010 | |
| NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2010.08.001 | 2010 |
| Ex vivo expansion of umbilical cord blood for transplantation | 10.1016/j.beha.2010.06.004 | 2010 |
| Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation | 10.1200/jco.2007.15.8865 | 2009 |
| Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia | 10.1002/cncr.24198 | 2009 |
| Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome | 10.1038/bmt.2008.400 | 2009 |
| Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies | 10.3324/haematol.13756 | 2009 |
| Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT | 10.1038/bmt.2008.379 | 2009 |
| Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes | 10.1016/j.bbmt.2009.01.021 | 2009 |
| Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma | 10.1002/ajh.21400 | 2009 |
| Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma | 10.1016/j.bbmt.2009.02.011 | 2009 |
| Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic Stem Cell Transplantation | 10.1016/j.bbmt.2009.05.006 | 2009 |
| High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation | 10.1097/TP.0b013e3181b9d710 | 2009 |
| Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia | 10.1016/j.bbmt.2009.07.008 | 2009 |
| Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution | 10.1038/leu.2009.181 | 2009 |
| Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease | 10.1182/blood-2009-05-223172 | 2009 |
| Transplante de células-tronco de doador não aparentado com sucesso após transplante de células de cordão umbilical não aparentado em paciente com leucemia linfocítica aguda: À procura do efeito enxerto versus leucemia | 10.1590/s1516-84842009000400020 | 2009 |
| Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction | 10.1016/j.bbmt.2009.06.001 | 2009 |
| Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer | 10.1007/s12185-009-0439-6 | 2009 |
| A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease | 10.1016/j.bbmt.2009.08.003 | 2009 |
| The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review | 10.1016/j.bbmt.2008.12.003 | 2009 |
| Aging, Acute Myelogenous Leukemia, and Allogeneic Transplantation: Do They Belong in the Same Sentence? | 10.3816/clm.2009.n.057 | 2009 |
| Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia | 10.1097/01.cco.0000357469.83960.12 | 2009 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era | 10.3816/CLM.2009.s.021 | 2009 |
| Ex vivo expansion of cord blood | 10.1038/bmt.2009.284 | 2009 |
| Cord blood transplants | 2009 | |
| SOS: too many irons in the fire! | 10.1182/blood-2009-05-221820 | 2009 |
| Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial | 10.1038/sj.bmt.1705979 | 2008 |
| Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience | 10.3324/haematol.11828 | 2008 |
| Altered gene expression in busulfan-resistant human myeloid leukemia | 10.1016/j.leukres.2008.01.016 | 2008 |
| Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model? | 10.2217/17460751.3.2.157 | 2008 |
| High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age | 10.1093/annonc/mdm608 | 2008 |
| Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS | 10.1016/j.bbmt.2008.03.009 | 2008 |
| Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT | 10.1038/bmt.2008.79 | 2008 |
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab | 10.1182/blood-2008-01-136242 | 2008 |
| Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation | 10.1111/j.1365-2141.2008.07277.x | 2008 |
| BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias | 10.1182/blood-2008-04-148791 | 2008 |
| Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML | 10.1038/bmt.2008.376 | 2008 |
| Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia | 10.1586/14737140.8.5.785 | 2008 |
| Novel Preparative Regimens in Hematopoietic Stem Cell Transplantation | 10.2174/138161208785061409 | 2008 |
| Simultaneously optimizing dose and schedule of a new cytotoxic agent | 10.1177/1740774507076934 | 2007 |
| Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing Schedule | 10.1016/j.bbmt.2006.08.037 | 2007 |
| Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) | 10.1182/blood-2006-05-021907 | 2007 |
| Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan | 10.1016/j.bbmt.2006.11.024 | 2007 |
| Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia | 10.1002/cncr.22778 | 2007 |
| Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies | 10.1038/sj.bmt.1705699 | 2007 |
| Hyperacute GVHD: risk factors, outcomes, and clinical implications | 10.1182/blood-2006-07-034348 | 2007 |
| Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation | 10.1038/sj.bmt.1705751 | 2007 |
| Microbial contamination of hematopoietic progenitor cell products: clinical outcome | 10.1038/sj.bmt.1705731 | 2007 |
| Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation | 10.1038/sj.leu.2404828 | 2007 |
| Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia | 10.1111/j.1365-2141.2007.06591.x | 2007 |
| Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia | 10.1182/blood-2007-04-085969 | 2007 |
| Infections in 100 Cord Blood Transplantations | 10.1097/MD.0b013e31815c52b0 | 2007 |
| Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing | 10.1182/blood-2007-05-092130 | 2007 |
| Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences | 10.1182/blood-2007-06-096966 | 2007 |
| Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome | 10.1038/sj.leu.2405014 | 2007 |
| Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation | 2007 | |
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | 10.1002/cncr.21700 | 2006 |
| A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts | 10.1038/sj.bmt.1705284 | 2006 |
| High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma | 10.1080/10428190500468584 | 2006 |
| Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells | 10.1038/sj.bmt.1705258 | 2006 |
| Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD | 10.1182/blood-2005-09-3907 | 2006 |
| Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity | 10.1080/14653240600620812 | 2006 |
| Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy | 10.1038/sj.bmt.1705435 | 2006 |
| Unrelated cord blood transplants in adults with hematologic malignancies | 2006 | |
| Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation | 10.1038/sj.bmt.1705448 | 2006 |
| AML-loaded DC generate Th1-type cellular immune responses in vitro | 10.1080/14653240600620093 | 2006 |
| Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia | 10.1038/sj.bmt.1705425 | 2006 |
| Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure | 10.1182/blood-2006-02-001933 | 2006 |
| Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies | 10.1038/sj.bmt.1705467 | 2006 |
| Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | 10.1053/j.seminhematol.2006.01.004 | 2006 |
| Strategies for widening the use of cord blood in hematopoietic stem cell transplantation | 2006 | |
| Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation | 10.1016/j.bbmt.2004.10.008 | 2005 |
| Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience | 10.1002/cncr.21032 | 2005 |
| Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas. | 2005 | |
| Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia | 10.1038/sj.bmt.1705011 | 2005 |
| Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen | 10.1038/sj.bmt.1704942 | 2005 |
| Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients | 10.1038/sj.bmt.1705090 | 2005 |
| Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease | 10.1111/j.1365-2141.2005.05616.x | 2005 |
| Ex vivo expansion of umbilical cord blood | 10.1080/14653240510027172 | 2005 |
| Secondary malignancies after hematopoietic stem cell transplantation | 10.1016/j.critrevonc.2005.03.014 | 2005 |
| Comorbidity indices in hematopoietic stem cell transplantation: a new report card | 10.1038/sj.bmt.1705041 | 2005 |
| Hemorrhagic Cystitis After Allogeneic HSCT: Donor Type matters | 2004 | |
| Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation | 10.1016/j.bbmt.2003.10.006 | 2004 |
| High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma | 10.1080/10428190310001603957 | 2004 |
| Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD | 2004 | |
| Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant | 10.1038/sj.bmt.1704645 | 2004 |
| Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia | 10.1056/nejmoa041469 | 2004 |
| Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia | 10.1038/sj.bmt.1704472 | 2004 |
| Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS | 10.1182/blood-2004-02-0414 | 2004 |
| Non-Ablative versus Reduced Intensity Conditioning Regimens in the Treatment of Acute Myeloid Leukemias. Dose is Relevant for Long-Term Disease Control after Allogeneic Hematopoietic Stem Cell Transplantation. | 2004 | |
| Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response | 10.1038/sj.bmt.1704621 | 2004 |
| Ex-vivo purging of hematopoietic stem cells | 2004 | |
| Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation | 10.1046/j.1365-2141.2003.04447.x | 2003 |
| Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias | 10.1002/cncr.11184 | 2003 |
| Lymphocyte function from peripheral blood stem cell donors in inhibited by activated granulocytes | 10.1080/1465324031000225 | 2003 |
| Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years | 10.1182/blood-2003-03-0855 | 2003 |
| West Nile Encephalitis in 2 Hematopoietic Stem Cell Transplant Recipients: Case Series and Literature Review | 10.1086/378278 | 2003 |
| Rapid induction of complete donor chimerism and low treatment-related mortality by the use of fludarabine and melphalan in nonmyeloablative allogeneic stem cell transplantation for metastatic breast cancer and renal cell carcinoma | 2003 | |
| Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant | 10.1038/sj.leu.2403163 | 2003 |
| Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma | 10.1034/j.1600-0609.2003.00125.x | 2003 |
| Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit | 10.1016/j.bbmt.2003.09.001 | 2003 |
| Treatment of Relapsing Refractory Diffuse Large Cell Lymphoma After Matched Unrelated Donor Bone Marrow Transplant with Immunosuppression Withdrawal and Rituximab | 10.1080/1042819031000067936 | 2003 |
| Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications | 2003 | |
| Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma | 2002 | |
| STI571 Therapy for relapse after allogeneic stem-cell transplantation for chronic myelogenous leukemia | 2002 | |
| Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units | 10.1046/j.1365-2141.2002.03893.x | 2002 |
| Busulfan systemic exposure relative to regimen-related toxicity and acute graft vs. host disease; defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia | 2002 | |
| Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation | 10.1038/sj.bmt.1703711 | 2002 |
| Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia | 2002 | |
| Cord blood transplantation | 10.1097/00075200-200209000-00013 | 2002 |
| Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease | 2001 | |
| Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas | 10.1200/JCO.2001.19.17.3766 | 2001 |
| UNRELATED DONOR HEMATOPOIETIC TRANSPLANTATION | 10.1046/j.1468-0734.2001.00035.x | 2001 |
| High dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant | 2000 | |
| Tumor de bexiga localmente avancado: uma revisão das opções terapêuticas | 1999 | |
| High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. | 10.1200/JCO.1998.16.1.63 | 1998 |
| Comparison of referring and tertiary cancer center physicians'diagnoses in patients with leukemia | 1998 | |
| Chronic lymphocytic leukemia in the young patient | 1998 | |
| Management of lymphoma recurrence after allogeneic blood and marrow transplantation for non Hodgkin's Lymphoma: the relevance of graft versus lymphoma effect | 1997 | |
| Phase I-II Study of Gamma Interferon and 5-Fluorouracil for Patients with Metastatic Renal Cell Carcinoma | 10.1089/cbr.1997.12.365 | 1997 |
| Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. | 1997 | |
| Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center | 10.1002/(SICI)1097-0142(19971201)80:11+<2176::AID-CNCR2>3.3.CO;2-R | 1997 |
| Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above | 10.1046/j.1365-2141.1996.4771012.x | 1996 |
| Intralobar pulmonary sequestration | 1988 |
Eventos:
(0.00% eventos com DOI)